107 related articles for article (PubMed ID: 12031830)
21. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
22. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
23. Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031).
Light DR; Guilford WJ
Curr Top Med Chem; 2001 Jun; 1(2):121-36. PubMed ID: 11899248
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N²-Thiophenecarbonyl- and N²-Tosylanthranilamides.
Lee SH; Lee W; Nguyen T; Um IS; Bae JS; Ma E
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561744
[TBL] [Abstract][Full Text] [Related]
25. Antithrombotic activities of oroxylin A in vitro and in vivo.
Ku SK; Lee IC; Bae JS
Arch Pharm Res; 2014 May; 37(5):679-86. PubMed ID: 23963976
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
28. Experimental study on anticoagulant and antiplatelet aggregation activity of a chemically sulfated marine polysaccharide YCP.
Han F; Yao W; Yang X; Liu X; Gao X
Int J Biol Macromol; 2005 Sep; 36(4):201-7. PubMed ID: 16102810
[TBL] [Abstract][Full Text] [Related]
29. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
Deinum J; Mattsson C; Inghardt T; Elg M
Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic activities of pellitorine in vitro and in vivo.
Ku SK; Lee IC; Kim JA; Bae JS
Fitoterapia; 2013 Dec; 91():1-8. PubMed ID: 23973654
[TBL] [Abstract][Full Text] [Related]
31. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
Chu V; Brown K; Colussi D; Gao J; Bostwick J; Kasiewski C; Bentley R; Morgan S; Guertin K; Pauls HW; Gong Y; Zulli A; Perrone MH; Dunwiddie CT; Leadley RJ
Thromb Res; 2001 Aug; 103(4):309-24. PubMed ID: 11562341
[TBL] [Abstract][Full Text] [Related]
33. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
34. Effect of Toona microcarpa Harms leaf extract on the coagulation system.
Chen H; Jin M; Wang YF; Wang YQ; Meng L; Li R; Wang JP; Gao L; Kong Y; Wei JF
Biomed Res Int; 2014; 2014():615363. PubMed ID: 24818147
[TBL] [Abstract][Full Text] [Related]
35. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK; Becker RC; Kleiman NS; Hochman JS; Bovill EG; Lincoff AM; Gerstenblith G; Dzavik V; Gardner LH; Hasselblad V; Zillman LA; Shimoto Y; Robertson TL; Kunitada S; Armstrong PW; Harrington RA
Circulation; 2002 May; 105(20):2385-91. PubMed ID: 12021225
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD
Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907
[TBL] [Abstract][Full Text] [Related]
37. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
Adler M; Davey DD; Phillips GB; Kim SH; Jancarik J; Rumennik G; Light DR; Whitlow M
Biochemistry; 2000 Oct; 39(41):12534-42. PubMed ID: 11027132
[TBL] [Abstract][Full Text] [Related]
38. Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation.
Ku SK; Bae JS
Fitoterapia; 2014 Oct; 98():27-35. PubMed ID: 25020199
[TBL] [Abstract][Full Text] [Related]
39. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation?
Stürzebecher J; Stürzebecher U
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):152-6. PubMed ID: 2459011
[TBL] [Abstract][Full Text] [Related]
40. A new C-type lectin (RVsnaclec) purified from venom of Daboia russelii russelii shows anticoagulant activity via inhibition of FXa and concentration-dependent differential response to platelets in a Ca²⁺-independent manner.
Mukherjee AK; Dutta S; Mackessy SP
Thromb Res; 2014 Nov; 134(5):1150-6. PubMed ID: 25281435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
